Cargando…

Real-world treatment pattern and comprehensive comparative effectiveness of Endostar plus different chemotherapy in advanced patients with non-small cell lung cancer

Recombinant human endostatin (Endostar) plus vinorelbine/cisplatin (NP) had been approved for the treatment of non-small cell lung cancers (NSCLC). But the real-world treatment pattern and effectiveness of Endostar plus other combination chemotherapy, namely docetaxel/platinum (DP), gemcitabine/plat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jiang, Wei, Sun, Wei, Li, Wenhui, Gao, Jin, Wang, Hui, Zhou, Wei, Liang, Jing, Aa, Lixiang, Wang, Luhua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9237081/ https://www.ncbi.nlm.nih.gov/pubmed/35761010 http://dx.doi.org/10.1038/s41598-022-14222-w

Ejemplares similares

Systematic review and meta-analysis of Endostar (rh-endostatin) combined with chemotherapy versus chemotherapy alone for treating advanced non-small cell lung cancer
por: Biaoxue, Rong, et al.
Publicado: (2012)

Recombined humanized endostatin (Endostar) combined with chemotherapy for advanced bone and soft tissue sarcomas in stage IV
por: Xing, Peipei, et al.
Publicado: (2016)

Effect of Endostar combined with chemotherapy in advanced well-differentiated pancreatic neuroendocrine tumors
por: Cheng, Yue-Juan, et al.
Publicado: (2018)

Endostar (rh‐endostatin) versus placebo in combination with vinorelbine plus cisplatin chemotherapy regimen in treatment of advanced non‐small cell lung cancer: A meta‐analysis
por: An, Jihong, et al.
Publicado: (2018)

Efficacy of concurrent chemoradiotherapy plus Endostar compared with concurrent chemoradiotherapy in the treatment of locally advanced nasopharyngeal carcinoma: a retrospective study
por: Yin, Yuanxiu, et al.
Publicado: (2022)

Suitable carriers for encapsulation and distribution of endostar: comparison of endostar-loaded particulate carriers
por: Chen, Weijie, et al.
Publicado: (2011)

Comparison of Endostar continuous versus intermittent intravenous infusion in combination with first‐line chemotherapy in patients with advanced non‐small cell lung cancer
por: Cheng, Yuan, et al.
Publicado: (2019)

A retrospective study on the efficacy and safety of Endostar with chemotherapy in EGFR-TKI-resistant NSCLC
por: Han, Bing, et al.
Publicado: (2023)

Endostar Combined with Gemcitabine and Cisplatin Chemotherapy for Patients with Metastatic Nasopharyngeal Carcinoma: an Update
por: Jin, Ting, et al.
Publicado: (2018)

Endostar Rebuilding Vascular Homeostasis and Enhancing Chemotherapy Efficacy in Cervical Cancer Treatment
por: Guan, Liming
Publicado: (2020)

Combined chemotherapy plus endostar with sequential stereotactic radiotherapy as salvage treatment for recurrent esophageal cancer with severe dyspnea: A case report and review of the literature
por: XU, MINGFANG, et al.
Publicado: (2014)

Efficacy and toxicities of gemcitabine and cisplatin combined with endostar in advanced thymoma and thymic carcinoma
por: Wang, Yang, et al.
Publicado: (2018)

Endostar, an Antiangiogenesis Inhibitor, Combined With Chemoradiotherapy for Locally Advanced Cervical Cancer
por: Lu, Heming, et al.
Publicado: (2022)

Successful treatment of relapsed testicular embryonal rhabdomyosarcoma with Endostar and traditional chemotherapy: a case report
por: Han, Tao, et al.
Publicado: (2018)

First-Line Pembrolizumab Plus Chemotherapy for Advanced Squamous NSCLC: Real-World Outcomes at U.S. Oncology Practices
por: Liu, Stephen V., et al.
Publicado: (2022)

Endostar plus pembrolizumab combined with a platinum-based dual chemotherapy regime for advanced pulmonary large-cell neuroendocrine carcinoma as a first-line treatment: A case report
por: Zhang, Sijia, et al.
Publicado: (2022)

Hepatic arterial infusion chemotherapy plus regorafenib in advanced colorectal cancer: a real-world retrospective study
por: Cao, Guang, et al.
Publicado: (2022)

A real-world evidence of efficacy of palliative gastrectomy plus chemotherapy in metastatic gastric cancer patients
por: Yang, Lu-Ping, et al.
Publicado: (2019)

Immune checkpoint inhibitors plus chemotherapy in patients with locally advanced or metastatic pulmonary sarcomatoid carcinoma: a multicentric real-world study
por: Zhou, Fei, et al.
Publicado: (2022)

Efficacy and outcome analysis: Combination of Endostar and chemotherapy as a neoadjuvant treatment of stage IIIA/IIIB squamous cell lung cancer
por: Cao, Feiyi, et al.
Publicado: (2023)

Efficacy and safety of rh‐endostatin (Endostar) combined with pemetrexed/cisplatin followed by rh‐endostatin plus pemetrexed maintenance in non‐small cell lung cancer: A retrospective comparison with standard chemotherapy
por: Zhou, Shengyu, et al.
Publicado: (2018)

Endostar combined with chemotherapy in a pediatric osteosarcoma with pulmonary metastasis and malignant pleural effusion: A case report
por: Jiang, Sujing, et al.
Publicado: (2017)

Metronomic chemotherapy of cyclophosphamide plus methotrexate for advanced breast cancer: Real‐world data analyses and experience of one center
por: Lu, Qianyi, et al.
Publicado: (2020)

Baseline platelet counts and derived inflammatory biomarkers: prognostic relevance in metastatic melanoma patients receiving Endostar plus dacarbazine and cisplatin
por: Yang, Lingge, et al.
Publicado: (2019)

Real-World Cost-Effectiveness Analysis of Gemcitabine and Cisplatin Compared to Docetaxel and Cisplatin Plus Fluorouracil Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
por: Yang, Jiangping, et al.
Publicado: (2020)

PD-1/PD-L1 inhibitors plus anti-angiogenic agents with or without chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy as second or later-line treatment for patients with advanced non-small cell lung cancer: A real-world retrospective cohort study
por: Chen, Shubin, et al.
Publicado: (2022)

The efficacy and safety of Endostar combined with chemoradiotherapy for patients with advanced, locally recurrent nasopharyngeal carcinoma
por: Guan, Ying, et al.
Publicado: (2015)

Endostar continuous versus intermittent intravenous infusion combined with chemotherapy for advanced NSCLC: a systematic review and meta-analysis including non-randomized studies
por: Wang, Bo, et al.
Publicado: (2020)

Treatment Patterns and Survival of Patients With Advanced Non-Small Cell Lung Cancer Guided by Comprehensive Genomic Profiling: Real-World Single-Institute Study in China
por: Lv, Weize, et al.
Publicado: (2021)

Thoracic perfusion of lobaplatin combined with endostar for treating malignant pleural effusions: A meta-analysis and systematic review
por: Wang, Cheng-Qian, et al.
Publicado: (2022)

Comparison of bevacizumab plus chemotherapy with chemotherapy alone in advanced non-small-lung cancer patients
por: Tang, Ning, et al.
Publicado: (2016)

Efficacy and safety evaluation of neoadjuvant immunotherapy plus chemotherapy for resectable non–small cell lung cancer in real world
por: Fang, Min, et al.
Publicado: (2023)

The Therapeuatic Effect of Endostar on Soft Carotid Plaque Neovascularization in Patients with Non-small Cell Lung Cancer
por: Pu, Zhaoxia, et al.
Publicado: (2015)

Programmed cell death 1 inhibitor plus chemotherapy vs. chemotherapy in advanced drive-gene-negative non-small-cell lung cancer patients: A real-world study
por: Li, Ying, et al.
Publicado: (2022)

Induction chemotherapy with sequential nimotuzumab plus concurrent chemoradiotherapy in advanced nasopharyngeal carcinoma: A retrospective real-world study
por: Jiang, Danxian, et al.
Publicado: (2023)

Intensity-modulated radiotherapy combined with endostar has similar efficacy but weaker acute adverse reactions than IMRT combined with chemotherapy in the treatment of locally advanced nasopharyngeal carcinoma
por: Kang, Min, et al.
Publicado: (2018)

A Real-World Study in Advanced Non–Small Cell Lung Cancer with KRAS Mutations
por: Lei, Lei, et al.
Publicado: (2019)

Endostar (rh‐endostatin) improves efficacy of concurrent chemoradiotherapy for locally advanced non‐small cell lung cancer: A systematic review and meta‐analysis
por: Yuan, Meng, et al.
Publicado: (2021)

Autophagy inhibition contributes to Endostar sensitization in esophageal squamous cell carcinoma
por: Han, Xinghua, et al.
Publicado: (2017)

Comprehensive Evaluation of the Anti-Angiogenic and Anti-Neoplastic Effects of Endostar on Liver Cancer through Optical Molecular Imaging
por: Zhang, Qian, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ghs7tb2jjrqndt0kpdbk6rvl4i